Schedule 13G ownership disclosure
ADAPTIMMUNE THERAPEUTICS PLC
Security class unavailable · CUSIP: 00653A107
Event date: 2019-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 168,000,000
- Percent of class
- 26.6500%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-20-001127
- Form type
- SC 13G
- Filer
- Adaptimmune Therapeutics PLC
- CIK
- CIK 1621227
- Filed
- Feb 14, 2020
- Reporting period
- Dec 31, 2019
- Description
- Schedule 13G beneficial ownership